EMPOWERING
MUSCLE
EMPOWERING
LIVES

Avonne, diagnosed with oHCM

Cytokinetics®

Q1 2026
Financial Results

May 5, 2026

Actual patient who consented to use of their name, image, and condition.

Today's Agenda

Introduction	**Diane Weiser** SVP, Corporate Affairs
First Quarter 2026 Highlights	**Robert Blum** President & CEO
Commercial Updates	**Andrew Callos** EVP, Chief Commercial Officer
Clinical Updates	**Fady Malik, M.D., Ph.D.** EVP, Research & Development
Ongoing Clinical Development	**Stuart Kupfer, M.D.** SVP, Chief Medical Officer
Financial Results	**Sung Lee** EVP, Chief Financial Officer
Closing Comments	**Robert Blum** President & CEO

Forward-Looking Statements

This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; in particular, clinical trial initiation, design, enrollment, conduct, progress, continuation, completion, timing and results; regulatory submissions for *aficamten* as a treatment for non-obstructive hypertrophic cardiomyopathy,, review processes, approval timing and outcomes, including with respect to supplemental applications and approvals in jurisdictions outside the United States; the scope, expansion, modification, durability or continuation of labeling and promotional claims; commercial readiness, launch timing, market access and reimbursement; anticipated patient, prescriber and payer adoption; expectations regarding market opportunity, growth and market share; pipeline development and expansion into additional indications or geographies; access to and use of capital; and Cytokinetics' business strategy, objectives and future plans.

Such statements are based on management's current expectations and assumptions; however, actual results may differ materially due to various risks and uncertainties, including, but not limited to, uncertainties inherent in drug development and commercialization; the timing, conduct and outcomes of clinical trials; regulatory review and approval processes in the United States and other jurisdictions; differences in regulatory requirements, labeling, market access or promotional restrictions across jurisdictions; the ability to obtain, expand, maintain or continue desired labeling, promotional claims or commercial positioning for approved products; potential legal, intellectual property or regulatory constraints affecting commercialization and marketing claims; patient and prescriber acceptance of MYQORZO as compared to alternative therapies; the availability and terms of reimbursement from commercial and government payers; manufacturing, supply and distribution risks; competition; and the availability of sufficient capital to execute Cytokinetics' business plans. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission (the "SEC").

Disclaimer: The assumptions used in the preparation of this presentation, although considered reasonable by us at the time of preparation, may prove to be incorrect. You are cautioned that the information is based on assumptions as to many factors and that actual results may vary from the results projected, and such variations may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained herein or rely on them as predictions of future events.

The trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Certain information contained in this presentation relates to or is based on studies, publications and other data obtained from third-party sources, as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources.

Robert Blum

President and CEO

Strong Start to 2026

Q1 2026 & Recent Highlights

- **MYQORZO® now approved** in U.S., EU and China
- Positive topline results from **ACACIA-HCM** reported in April 2026
- **U.S. commercial launch of MYQORZO** underway with $4.8 million in sales in first 9 weeks
- **NDS for MYQORZO** under review in Canada & MAA submitted in Switzerland; **6 HTA dossiers submitted**
- **MAPLE-HCM sNDA** on file with FDA; PDUFA date of November 14, 2026

2026 Key Activities

- **Continue U.S. commercial launch** of MYQORZO
- **Launch MYQORZO in Germany** in Q2
- Secure additional **global approvals for *aficamten*** in oHCM
- Meet with regulatory authorities, including FDA, to discuss the results of **ACACIA-HCM** and plans for submitting an sNDA
- Advance **specialty cardiology pipeline**

NDS: New Drug Submission; MAA: Marketing Authorization Application; HTA: Health Technology Assessment; sNDA: Supplemental New Drug Application; FDA: U.S. Food & Drug Administration; PDUFA: Prescription Drug User Fee Act; oHCM: obstructive hypertrophic cardiomyopathy
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Andrew Callos

EVP, Chief Commercial Officer

Cytokinetics®

MYQORZO™
(aficamten) 5·10·15·20 mg tablets

Now Available

FDA-approved for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms

FDA: U.S. Food & Drug Administration; oHCM: obstructive hypertrophic cardiomyopathy
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Foundation of Clinical Differentiation

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

Rapid & sustained
symptom improvement and reduction in obstruction



Flexibility to rapidly titrate
as early as 2 weeks, with flexible monitoring schedule

No treatment interruptions
or worsening HF events observed in patients with LVEF <50% in SEQUOIA-HCM

HF: heart failure; LVEF: left ventricular ejection fraction
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Strong HCP Awareness and Perception



HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use MYQORZO safely and effectively. See full prescribing information for MYQORZO.

MYQORZO™ (aficamten) tablets, for oral use
Initial U.S. Approval: 2025

WARNING: RISK OF HEART FAILURE
See full prescribing information for complete boxed warning.

- **MYQORZO can cause heart failure due to systolic dysfunction. (5.1)**
- **Echocardiogram assessments of left ventricular ejection fraction (LVEF) are required before and during MYQORZO use. (2.1)**
- **Initiation in patients with left ventricular ejection fraction (LVEF) <55% is not recommended. (2.1)**
- **Decrease dose if LVEF <50% and ≥40%. Interrupt dosing if LVEF <40% or if worsening clinical status. (2.2)**
- **MYQORZO is available only through a restricted program called the MYQORZO REMS Program. (5.2)**

----------INDICATIONS AND USAGE----------

MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. (1)

----------DOSAGE AND ADMINISTRATION----------

- Recommended starting dose is 5 mg orally once daily. (2.1)
- Dosage is individualized based on echocardiographic assessments and clinical status. Refer to Full Prescribing Information for instructions on dosage modification. (2.1, 2.2)

----------DOSAGE FORMS AND STRENGTHS----------

Film-coated tablets: 5 mg, 10 mg, 15 mg, 20 mg. (3)

----------CONTRAINDICATIONS----------

- Rifampin (4)

----------WARNINGS AND PRECAUTIONS----------

Risk of Heart Failure: Consider decreasing dose or dose interruption in patients with serious intercurrent illness. (2.2, 5.1)
Drug Interactions Leading to Increased Risk of Heart Failure or Loss of Effectiveness: Advise patients of the potential for drug interactions. (2.3, 5.3, 17)

----------ADVERSE REACTIONS----------

The most common adverse reaction was hypertension (8%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Cytokinetics at 1-833-633-2986 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----------DRUG INTERACTIONS----------

Drugs that inhibit multiple pathways of MYQORZO elimination, strong CYP2C9 inhibitors, or moderate-to-strong CYP3A inducers may increase risk of heart failure. MYQORZO dose reduction and additional monitoring may be required when initiating or discontinuing these drugs. (2.3, 7.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Medication Guide.

Revised: 12/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

80% of treating HCPs*
report having seen MYQORZO Prescribing Information (PI)

MYQORZO Label Viewed Favorably by HCPs**

- ✓ Rapid dose titration and reversibility
- ✓ Flexibility in echo monitoring
- ✓ No clinically meaningful drug-drug interactions
- ✓ No DDI monitoring within REMS

HCP: healthcare provider; DDI: drug-drug interactions; REMS: Risk Evaluation and Mitigation Strategies
** On an aided basis*
*** HCP Market Research Pulse Survey Wave 2 – Mar'26*
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Initial Focus on High Volume CMI Prescribers

HCPs for Personal and Non-Personal Engagement



Other CMI non-users
Non-personal promotion

CMI nonusers who treat HCM
Personal promotion

Low volume CMI prescribers
~20% of CMI TRx
Personal promotion

~40% detailed in Q1 '26

High volume CMI prescribers
~80% of CMI TRx
Personal promotion

>90% detailed in Q1 '26

- ✓ At launch, we have a **greater emphasis on the top CMI prescribers to build share and depth of prescribing**
- ✓ By end of 2026 we aim to achieve **>50% new-to-brand prescription share**

CMI: cardiac myosin inhibitor; HCP: healthcare provider; HCM: hypertrophic cardiomyopathy; TRx: total prescriptions
Source: Symphony Health Payer Prescriber Data (CAMZYOS Rx - Apr'22 – Dec'25) / Internal Data on CAS team engagement / Veeva - Call activity data
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Measuring Launch Velocity: 3 Key Metrics

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

Breadth and depth of HCP prescribing of MYQORZO®

Number of HCPs
prescribing MYQORZO

Volume of MYQORZO prescriptions
each HCP writes

Volume of patients prescribed MYQORZO

Number of patients
prescribed MYQORZO

HCP: healthcare provider
Based on internal revenue forecast informed by demand studies
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Key Metrics: Breadth & Depth of HCP Prescribing

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

Breadth of HCP Prescribing

As of 3/31/26 → *As of 4/30/26*

>275 → >425

HCPs prescribing MYQORZO

As of 3/31/26

~50%

high-volume CMI writers

Q1 Depth of HCP Prescribing

As of 3/31/26

2.4

Average prescriptions written per HCP

2.6

Average prescriptions written per high volume CMI writer

Potential Leading Indicator of Future Prescribing

As of 3/31/26

1,400+

REMS-certified HCPs

Q1 Exit Share (estimated)

As of 3/31/26

>30%

New-to-Brand share

Analysis based on projected third party syndicated data

HCP: healthcare provider; CMI: cardiac myosin inhibitor; KOL: Key Opinion Leader, REMS: Risk Evaluation and Mitigation Strategies
Source: MYQORZO internal patient prescription data) through Apr'30 (Specialty pharmacies and Integrated Delivery Networks (IDNs)/REMs Data from PPD
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Key Metrics: Volume of Patients

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

Volume of Patients

As of 3/31/26 **680** → *As of 4/30/26* **1,100**

Patients Prescribed MYQORZO

Paid Drug in Q1

>70%

Patients on therapy with a paid prescription*

<2 weeks

Average time to convert to paid prescription

Source: MYQORZO internal patient prescription data through Apr'30 (Specialty pharmacies and Integrated Delivery Networks (IDNs))
**Paid prescriptions calculated using dispensed Rxs*
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Market Access Strategy

Grow CMI class & compete via clinical differentiation

MYQORZO™ (aficamten) 5·10·15·20mg tablets

MYQORZO® Q1 Payor Mix



Securing Market Access

Q1 2026 — Ongoing payor engagement

Q2 2026 — **Secured comparable access for nearly 90% of Medicare lives,** expect parity by end of Q2 2026

Q3 2026 — Expect to reach **50% of commercial lives covered** by early Q3 2026

Q4 2026 — Expect to achieve **parity commercial access** by Q4 2026

CMI: cardiac myosin inhibitor
**Government = 66%*
Source: Managed Markets Insights & Technology, LLC (MMIT); MMIT Analytics Platform
Please see full Prescribing Information, including Boxed WARNING and Medication Guide

Cytokinetics®

Advancing Global Availability in 2026

MYQORZO™ (aficamten) 5·10·15·20mg tablets

United States

Approved by FDA for adults with symptomatic oHCM to improve functional capacity and symptoms

LAUNCHED JAN 2026

Cytokinetics

China

Approved by NMPA for adults with NYHA class II-III oHCM to improve exercise capacity and symptoms

LAUNCHED JAN 2026

Cytokinetics

sanofi

European Union

Approved by the European Commission for symptomatic (NYHA class II-III) oHCM in adult patients

LAUNCH EXPECTED IN GERMANY Q2 2026

Cytokinetics

Pending Regulatory Approval

Canada
New Drug Submission under review; expect to receive decision in 2H 2026

Switzerland
MAA submitted Q1 2026

Cytokinetics

Clinical Trials Ongoing

Japan
Phase 3 clinical trials ongoing in oHCM & nHCM

Cytokinetics

BAYER

FDA: U.S. Food & Drug Administration; oHCM: obstructive hypertrophic cardiomyopathy; NMPA: National Medical Products Administration; NYHA: New York Heart Association; MAA: Marketing Authorization Application; EMA: European Medicines Agency; CHMP: Committee for Medicinal Products for Human Use; nHCM: non-obstructive hypertrophic cardiomyopathy

MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

Fady Malik, M.D., Ph.D.

EVP, Research & Development

Cytokinetics®

ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM

Full results to be presented at upcoming medical meeting

Primary Endpoints	Change from Baseline to Week 36 LSM (95% CI]		*Aficamten* vs Placebo LSM (95% CI)	p-value
	Aficamten	Placebo		
KCCQ-CSS	11.4 (9.6 – 13.2)	8.4 (6.6 – 10.2)	**3.0 (0.5 - 5.5)**	0.021
pVO_2 (ml/kg/min)	0.64 (0.32 – 0.95)	-0.03 (-0.35 – 0.28)	**0.67 (0.22 - 1.1)**	0.003

Statistically significant (p<0.001) improvements observed in key secondary endpoints:

1. Proportion of participants with improvements in NYHA Functional Class
2. Composite z-score of ventilatory efficiency and pVO_2
3. N-terminal pro-B-type natriuretic peptide (NT-proBNP)

No new safety signals identified

% participants completing planned dosing:
Similar between groups
(88.4% on *aficamten* vs. 90.3% on placebo)

LVEF <50%:
27 (10%) on *aficamten* vs. 2 (1%) on placebo;

2 participants on *aficamten* had a serious adverse event of HF associated with LVEF <50%

Treatment Interruptions
Treatment interruptions due to LVEF <40% occurred in 3% of patients on *aficamten*

nHCM: non-obstructive hypertrophic cardiomyopathy; pVO_2: peak oxygen uptake; LSM: least squares mean; CI: confidence interval; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; NYHA: New York Heart Association; CV: cardiovascular; HF: heart failure; LVEF: left ventricular ejection fraction; AE: adverse event

MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM

Robust & consistent improvements throughout treatment period

LS Mean Change from Baseline in KCCQ-CSS



** EoT visit includes participants who completed treatment at any time point beyond week 36*

Change from Baseline to Week 36 in pVO_2



nHCM: non-obstructive hypertrophic cardiomyopathy; LS: least squares; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; LSM: least squares mean; EOT: End of Treatment; EOS: End of Study; pVO_2: peak oxygen uptake

MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

Cytokinetics®

Stuart Kupfer, M.D.

SVP, Chief Medical Officer

Cytokinetics®

Ongoing Programs for *Aficamten* in HCM

CAMELLIA-HCM

Phase 3 trial in
Japanese patients with oHCM

Enrollment complete, conduct ongoing

CEDAR HCM

Cytokinetics

Phase 2/3 trial in
pediatric & adolescent patients with oHCM

Expect to complete enrollment in adolescent cohort by end of 2026

ACACIA HCM

Japan Cohort

Cytokinetics

Phase 3 trial in
patients with nHCM

Conduct ongoing

oHCM: obstructive hypertrophic cardiomyopathy; nHCM: non-obstructive hypertrophic cardiomyopathy
MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

Phase 3 Confirmatory Clinical Trial Design

Currently enrolling

COMET-HF

COMET-HF: **C**onfirmation of ***O**mecamtiv **M**ecarbil* **E**fficacy **T**rial in **H**eart **F**ailure

- Primary endpoint: **time to CV death, HF events, transplant/LVAD, or stroke**
- **Enriching population for adherence** with OM run-in period
- **Pragmatic design elements:**
  - Remote clinic visits
  - Limited safety labs & ECGs
  - Streamlined eligibility and study conduct
  - Streamlined AE reporting



CV: cardiovascular; HF: heart failure; LVAD: left ventricular assist device; OM: omecamtiv mecarbil; ECG: electrocardiogram; AE: adverse event; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; PK: pharmacokinetics; KCCQ: Kansas City Cardiomyopathy Questionnaire

Omecamtiv mecarbil is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

Cytokinetics®

Phase 2 Study Schema

Currently enrolling

AMBER-HFpEF: Assessment of CK-586 in a **M**ulti-Center, **B**linded **E**valuation of Safety & Tolerability **R**esults in **HFpEF**

Enrolling HFpEF patients with:

- LVEF ≥ 60%
- Structural abnormality
- BMI < 40
- NYHA FC II or III
- NT-proBNP ≥ 300 (or ≥ 900 in AF)



HFpEF: heart failure with preserved ejection fraction; LVEF: left ventricular ejection fraction; BMI: body mass index; NYHA FC: New York Heart Association Functional Class; AF: atrial fibrillation; SoC: standard of care
Ulacamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.

Cytokinetics®

Sung Lee

EVP, Chief Financial Officer

Q1 2026 Financial Highlights

	Three months ended March 31, 2026	Three months ended March 31, 2025
MYQORZO® net product revenue	$4.8 m	-
Collaboration revenues	$2.6 m	$1.6 m
License and milestone revenues	$11.9 m	-
Total revenues	**$19.4 m**	**$1.6 m**
R&D expenses	$95.5 m	$98.3 m
SG&A expenses	$104.9 m	$57.4 m
Cost of goods sold	$0.2 m	-
Collaboration cost of revenues	$2.4 m	$1.6 m
Net loss	$206.0 m	$161.4 m

~$1.1B in cash, cash equivalents and investments as of March 31, 2026

R&D: Research & Development; SG&A: Selling, General & Administrative

2026 Financial Guidance

	Guidance Issued on Feb. 24, 2026
GAAP Combined R&D and SG&A Expense	**$830M to $870M**
Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A Expense	**$130M to $120M**

The financial guidance does not include: 1) collaboration expenses which can include reimbursed expenses and cost of inventory sales of *aficamten* to partners, 2) potential costs related to commercialization of *aficamten* in nHCM, and 3) the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities.

GAAP: Generally Accepted Accounting Principles; R&D: Research & Development; SG&A: Selling, General & Administrative; nHCM: non-obstructive hypertrophic cardiomyopathy

Robert Blum

President and CEO

Cytokinetics®

Positioned for Launch Velocity & Sustainable Growth

COMMERCIAL

MYQORZO™ (aficamten) 5·10·15·20 mg tablets

Approved for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms in U.S., China & Europe

RESEARCH & DEVELOPMENT

Muscle-directed platform with multi-program pipeline

Specialty Cardiology Franchise

sNDA for *aficamten* based on MAPLE-HCM under review with FDA, PDUFA November 14, 2026*

Potential for *aficamten* in nHCM based on positive topline results from **ACACIA-HCM**

Expansion & breadth: **CEDAR-HCM** (pediatric oHCM) enrolling, **FOREST-HCM** (HCM OLE) ongoing

Building specialty cardiology pipeline:

Omecamtiv mecarbil: Phase 3 confirmatory trial enrolling (**COMET-HF**)

Ulacamten: Phase 2 trial enrolling (**AMBER-HFpEF**)

STRONG FINANCIAL POSITION

~$1.1B
cash, cash equivalents & investments (as of 3/31/26)

Access to further capital:

- Eligible to draw up to **$175M** from tranche 7 loan provided by Royalty Pharma
- Up to **$150M** funding of a pivotal trial of *ulacamten* by Royalty Pharma at its option

oHCM: obstructive hypertrophic cardiomyopathy; sNDA: Supplemental New Drug Application; FDA: Food and Drug Administration; PDUFA: Prescription Drug User Fee Act; nHCM: non-obstructive hypertrophic cardiomyopathy; OLE: open label extension
**The results of MAPLE-HCM showed that the mean change in pVO_2 from baseline to Week 24 for aficamten was +1.1 mL/kg/min and -1.2 mL/kg/min for metoprolol (least-squares mean (LSM) difference between groups of 2.3 mL/kg/min (p<0.0001)*
MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.
Ulacamten, omecamtiv mecarbil and CK-089 are investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established.

2026 Expected Milestones

MYQORZO™ (aficamten) 5·10·15·20mg tablets	*Omecamtiv Mecarbil*	*Ulacamten*
Meet with regulatory authorities to discuss results from **ACACIA-HCM** & plans for submitting sNDA **Launch MYQORZO in Germany** in Q2 2026 sNDA for **MAPLE-HCM** PDUFA date November 14, 2026 Complete enrollment in the adolescent cohort of **CEDAR-HCM** in Q4 2026 Potential **Health Canada** decision on New Drug Submission in 2H 2026	Continue enrollment in **COMET-HF** through 2026	Complete enrollment in Cohort 1 of **AMBER-HFpEF** in 2H 2026

sNDA: Supplemental New Drug Application; oHCM: obstructive hypertrophic cardiomyopathy; PDUFA: Prescription Drug User Fee Act; HF: heart failure; HFpEF: heart failure with preserved ejection fraction
MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.
Ulacamten, omecamtiv mecarbil and CK-089 are investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established.
Timing of regulatory approvals is subject to regulatory review and may differ materially.

Cytokinetics®

Vi, diagnosed with oHCM

Cytokinetics®

Thank you

Actual patient who consented to use of their name, image, and condition.